[go: up one dir, main page]

PE20090161A1 - Anticuerpos monoclonales anti cxcl13 - Google Patents

Anticuerpos monoclonales anti cxcl13

Info

Publication number
PE20090161A1
PE20090161A1 PE2008000354A PE2008000354A PE20090161A1 PE 20090161 A1 PE20090161 A1 PE 20090161A1 PE 2008000354 A PE2008000354 A PE 2008000354A PE 2008000354 A PE2008000354 A PE 2008000354A PE 20090161 A1 PE20090161 A1 PE 20090161A1
Authority
PE
Peru
Prior art keywords
seq
amino acid
acid sequence
sequence corresponding
cxcl13
Prior art date
Application number
PE2008000354A
Other languages
English (en)
Inventor
Wendy Barker
Feenagh Anne Keyes
Original Assignee
Astrazeneca Ab
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Medimmune Ltd filed Critical Astrazeneca Ab
Publication of PE20090161A1 publication Critical patent/PE20090161A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

REFERIDA A UN MIEMBRO DE UNION PARA CXCL13 QUE TIENE LA SECUENCIA DE AMINOACIDOS CORRESPONDIENTE A LA SEQ ID N‘: 11, EL MIEMBRO DE UNION AISLADO COMPRENDE UN CONJUNTO DE CDR DEL ANTICUERPO 1: HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 Y LCDR3, DONDE HCDR1 TIENE LA SECUENCIA DE AMINOACIDOS CORRESPONDIENTE A LA SEQ ID N‘:3, HCDR2 TIENE LA SECUENCIA DE AMINOACIDOS CORRESPONDIENTE A LA SEQ ID N‘: 4, HCDR3 TIENE LA SECUENCIA DE AMINOACIDOS CORRESPONDIENTE A LA SEQ ID N‘: 5, LCDR1 TIENE LA SECUENCIA DE AMINOACIDOS CORRESPONDIENTE A LA SEQ ID N‘: 8, LCDR2 TIENE LA SECUENCIA DE AMINOACIDOS CORRESPONDIENTE A LA SEQ ID N‘: 9 Y LCDR3 TIENE LA SECUENCIA DE AMINOACIDOS CORRESPONDIENTE A LA SEQ ID N‘: 10. DICHOS COMPUESTOS SON UTILES EN EL TRATAMIENTO DE TRANSTORNOS ARTRITICOS
PE2008000354A 2007-02-21 2008-02-20 Anticuerpos monoclonales anti cxcl13 PE20090161A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89088807P 2007-02-21 2007-02-21
US90804107P 2007-03-26 2007-03-26

Publications (1)

Publication Number Publication Date
PE20090161A1 true PE20090161A1 (es) 2009-04-30

Family

ID=39409730

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000354A PE20090161A1 (es) 2007-02-21 2008-02-20 Anticuerpos monoclonales anti cxcl13

Country Status (16)

Country Link
US (2) US20080199481A1 (es)
EP (1) EP2129691A1 (es)
JP (1) JP2010519280A (es)
KR (1) KR20090114464A (es)
CN (1) CN101636413A (es)
AR (1) AR065433A1 (es)
AU (1) AU2008217581A1 (es)
BR (1) BRPI0807631A2 (es)
CA (1) CA2677878A1 (es)
EC (1) ECSP099572A (es)
IL (1) IL200168A0 (es)
MX (1) MX2009008608A (es)
PE (1) PE20090161A1 (es)
TW (1) TW200846369A (es)
UY (1) UY30932A1 (es)
WO (1) WO2008102123A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2539112C2 (ru) 2009-09-03 2015-01-10 Дженентек, Инк. Способы лечения, диагностики и мониторинга ревматоидного артрита
JP6097690B2 (ja) 2010-09-02 2017-03-15 ヴァクシネックス， インコーポレイテッド 抗ｃｘｃｌ１３抗体およびそれを用いる方法
CN106177930A (zh) * 2010-12-14 2016-12-07 吉安特科技股份有限公司 抗cxcl13抗体和抗cxcr5抗体在恶性肿瘤的治疗或检测中的用途
CN102221607B (zh) * 2011-03-29 2013-10-02 浙江大学医学院附属第一医院 一种抗体组合物及其应用
PT2734552T (pt) 2011-07-22 2025-01-29 Csl Behring Gmbh Anticorpos monoclonais inibidores do fator xii/xiia e suas utilizações
US9890213B2 (en) * 2012-03-02 2018-02-13 Vaccinex, Inc. Methods for the treatment of B cell-mediated inflammatory diseases
WO2014003744A1 (en) * 2012-06-27 2014-01-03 Morehouse School Of Medicine Anti-cxcl9, anti-cxcl 10, anti-cxcl 11, anti-cxcl 13, anti-cxcr3 and anti-cxcr5 agents for inflammatory disorder
US9790271B2 (en) 2013-01-31 2017-10-17 Vaccinex, Inc. Methods for increasing immunoglobulin A levels
JP6531893B2 (ja) * 2014-12-11 2019-06-19 国立大学法人 東京大学 濾胞性ヘルパーｔ細胞増加剤
CN104569409B (zh) * 2015-01-04 2017-01-11 深圳市艾瑞生物科技有限公司 一种快速定量检测髓过氧化物酶的均相荧光免疫试剂组及其制备方法
CN104569431B (zh) * 2015-01-04 2017-01-11 深圳市艾瑞生物科技有限公司 一种快速定量检测肌钙蛋白i的均相荧光免疫试剂组及其制备方法
CN104569374B (zh) * 2015-01-04 2017-01-11 深圳市艾瑞生物科技有限公司 一种快速定量检测c‑反应蛋白的均相荧光免疫试剂组及其制备方法
PE20210554A1 (es) 2017-12-01 2021-03-17 Pfizer Anticuerpos anti-cxcr5 y composiciones y usos de los mismos
CA3098509A1 (en) * 2018-09-18 2020-03-26 I-Mab Biopharma Us Limited Anti-cxcl13 antibodies for treating autoimmune diseases and cancer
WO2021026335A1 (en) * 2019-08-08 2021-02-11 The Trustees Of Indiana University Methods for identifying and treating urinary tract infections
WO2021252422A1 (en) 2020-06-11 2021-12-16 Vaccinex, Inc. Use of cxcl13 binding molecules to promote peripheral nerve regeneration
CN112521499B (zh) * 2020-12-24 2022-10-25 四川大学 抗cxcl13抗体及其用途
WO2023042314A1 (ja) * 2021-09-15 2023-03-23 和幸 吉崎 免疫異常性炎症性疾患を治療または予防するための組成物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5872215A (en) * 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
US5633149A (en) 1994-12-07 1997-05-27 Incyte Pharmaceuticals, Inc. Polynucleotide encoding novel chemokine expressed in inflamed adenoid
AU1916795A (en) 1995-02-08 1996-08-27 Human Genome Sciences, Inc. Human chemokine beta-11 and human chemokine alpha-1
CA2222280A1 (en) 1995-06-05 1996-12-12 Human Genome Sciences, Inc. Human chemokine beta-11 and human chemokine alpha-1
EP0950066A1 (en) 1996-10-04 1999-10-20 Human Genome Sciences, Inc. THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING DISEASE STATES WITH LEUKOCYTE ADHESION INHIBITOR-1 (LAI-1), AND CHEMOKINE BETA-11 (Ck$g(b)-11)
US6110695A (en) 1997-12-02 2000-08-29 The Regents Of The University Of California Modulating the interaction of the chemokine, B Lymphocyte Hemoattractant, and its Receptor, BLR1
CA2501422C (en) * 2004-04-29 2014-08-12 University Of Rochester Lymphoid chemokines in the diagnosis, monitoring and treatment of autoimmune disease
EP1703282A1 (en) 2005-03-15 2006-09-20 BRD, vertreten durch das BM für Gesundheit und Soziale Sicherung, Letztvertreten durch den Präsidenten des Robert-Koch-Inst. Method for ante mortem diagnosis of a TSE disease
GB0607774D0 (en) * 2006-04-20 2006-05-31 Renovo Group Plc Medicaments
CA2646902C (en) * 2006-04-21 2017-01-31 Centocor Inc. Cxcl13 antagonists and their use for the treatment of inflammatory diseases

Also Published As

Publication number Publication date
IL200168A0 (en) 2010-04-15
US20100086942A1 (en) 2010-04-08
US8182811B2 (en) 2012-05-22
WO2008102123A1 (en) 2008-08-28
UY30932A1 (es) 2009-01-30
KR20090114464A (ko) 2009-11-03
JP2010519280A (ja) 2010-06-03
BRPI0807631A2 (pt) 2014-06-03
US20080199481A1 (en) 2008-08-21
TW200846369A (en) 2008-12-01
AU2008217581A1 (en) 2008-08-28
AR065433A1 (es) 2009-06-10
ECSP099572A (es) 2009-10-30
MX2009008608A (es) 2009-09-16
CA2677878A1 (en) 2008-08-28
EP2129691A1 (en) 2009-12-09
CN101636413A (zh) 2010-01-27

Similar Documents

Publication Publication Date Title
PE20090161A1 (es) Anticuerpos monoclonales anti cxcl13
NZ610294A (en) Human antibodies to human tnf-like ligand 1a (tl1a)
RS53157B (en) SCLEROSTINE ANTIBODIES
NZ608660A (en) Anti-cd48 antibodies and uses thereof
IL277242B1 (en) Antibodies that bind cd39 and uses thereof
PE20200294A1 (es) Anticuerpos que se unen especificamente a pd-1 y metodos de uso
NZ603607A (en) Cgrp antibodies
PE20130817A1 (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos
NZ714313A (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
NZ600512A (en) Neutralizing prolactin receptor antibodies and their therapeutic use
NZ595011A (en) Humanised antibodies that bind and inhibit human DKK-1 protein and composition containing antibodies for treating DKK-1 associated diseases
PE20200011A1 (es) ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS
NZ609619A (en) Novel egfr-binding molecules and immunoconjugates thereof
NZ602780A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
NZ628943A (en) Human antibodies to clostridium difficile toxins
RS54111B1 (en) ANTI-ALPHA 2 INTEGRIN ANTIBODIES AND THEIR USES
NZ603529A (en) Antibodies to human gdf8
NZ598391A (en) Anti-hepcidin antibodies and uses thereof
NZ729913A (en) St2l antagonists and methods of use
NZ729158A (en) Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use
RS53661B1 (en) HIGH AFINITY ANTIBODY ANTIBODIES TO THE HUMAN NERVOUS FACTOR OF GROWTH
PE20081503A1 (es) Miembros de union para il-6
NZ592214A (en) Improved Interleukin-6 receptor antibody molecule
NZ598202A (en) High affinity human antibodies to human angiopoietin-2
PE20191408A1 (es) Proteinas de union a antigeno st2

Legal Events

Date Code Title Description
FA Abandonment or withdrawal